Author:
Lusvarghi Sabrina,Wang Wei,Herrup Rachel,Neerukonda Sabari Nath,Vassell Russell,Bentley Lisa,Eakin Ann E.,Erlandson Karl J.,Weiss Carol D.
Abstract
AbstractMutations in the spike protein of SARS-CoV-2 variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in several spike regions. To help predict antibody potency against emerging variants, we evaluated 25 clinical-stage therapeutic antibodies for neutralization activity against 60 pseudoviruses bearing spikes with single or multiple substitutions in several spike domains, including the full set of substitutions in B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), A.23.1 and R.1 variants. We found that 14 of 15 single antibodies were vulnerable to at least one RBD substitution, but most combination and polyclonal therapeutic antibodies remained potent. Key substitutions in variants with multiple spike substitutions predicted resistance, but the degree of resistance could be modified in unpredictable ways by other spike substitutions that may reside outside of the RBD. These findings highlight the importance of assessing antibody potency in the context of all substitutions in a variant and show that epistatic interactions in spike can modify virus susceptibility to therapeutic antibodies.ImportanceTherapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection (COVID-19), but their effectiveness may be reduced by virus variants with mutations affecting the spike protein. To help predict resistance to therapeutic antibodies in emerging variants, we profiled resistance patterns of 25 antibody products in late stages of clinical development against a large panel of variants that include single and multiple substitutions found in the spike protein. We found that the presence of a key substitution in variants with multiple spike substitutions can predict resistance against a variant, but that other substitutions can affect the degree of resistance in unpredictable ways. These finding highlight complex interactions among substitutions in the spike protein affecting virus neutralization and potentially virus entry into cells.
Publisher
Cold Spring Harbor Laboratory
Reference70 articles.
1. Anti-SARS-CoV-2 Antibody Products [Available from:https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/.
2. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial;Jama,2021
3. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
4. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab.
5. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Sotrovimab.